New obesity drug candidate gets first human test in UK

NCT ID NCT07220954

Ongoing Knowledge-focused Sponsor: AstraZeneca Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Aug 14, 2026 · Updated 2 times

Summary

This early-stage study is testing four different versions of an experimental drug called AZD6234 in 21 healthy adults who are overweight or obese. The goal is to see which formulation gets absorbed best into the blood and to check for any side effects. Participants will receive a single injection of each version in a random order. The study is not designed to test weight loss, but to gather important safety and dosing information for future trials.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: AZD6234
What this could lead to: If successful, this study could help identify the best formulation of AZD6234 for future weight management trials.
What could go wrong: This is a very early Phase 1 study with only 21 participants, focused on drug absorption and safety, not on weight loss. The drug may not work in larger trials or could have side effects.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for HEALTHY PARTICIPANTS are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

Obesity Overweight

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

HEALTHY PARTICIPANTS

Contacts and locations

Locations

Research Site

Ruddington, NG11 6JS, United Kingdom

More trials for these conditions

Other studies related to the condition(s) this trial covers.